Bristol-Myers Squibb stock gains as Q1 2026 growth portfolio drives guidance confidence

Bristol-Myers Squibb stock (ISIN US1078421011) has recently been trading close to 66.85 dollars on the New York Stock Exchange as of September 4, 2026, supported by improving fundamentals and a steadily strengthening growth portfolio in the first quarter of 2026.

Revenue growth and portfolio mix in Q1 2026

According to a Q1 2026 results overview compiled by Stock Titan, Bristol-Myers Squibb reported first quarter 2026 revenue of 11.5 billion dollars, an increase of 3 percent year on year, illustrating that the pharmaceutical group is back on a modest growth trajectory after a period of portfolio transition. The same Stock Titan summary highlights that the Growth Portfolio generated 6.2 billion dollars in Q1 2026, rising 12 percent compared with the prior-year period, while the Legacy Portfolio declined to 5.3 billion dollars, down 6 percent, underscoring the strategic shift toward newer therapies.

In terms of profitability, Bristol-Myers Squibb posted Q1 2026 GAAP diluted earnings per share of 1.31 dollars, up from 1.20 dollars in the first quarter of 2025, while non-GAAP EPS decreased from 1.80 dollars to 1.58 dollars due to higher research and development spending and lower other income. The Q1 2026 earnings discussion suggests that the company is deliberately investing in its pipeline while maintaining solid GAAP profitability, a trade-off investors need to watch as growth products scale.

Guidance and valuation context for Bristol-Myers Squibb stock

For the full year 2026, Bristol-Myers Squibb reaffirmed non-GAAP guidance calling for total revenue of about 46.0 to 47.5 billion dollars and non-GAAP diluted EPS of 6.05 to 6.35 dollars, with both metrics expected to trend toward the upper end of these ranges according to the same Stock Titan overview. This guidance reaffirmation gives investors a concrete earnings framework against which to judge the current share price near the mid-60 dollar range.

A valuation snapshot from Simply Wall St shows that Bristol-Myers Squibb’s share price has climbed 24.99 percent year to date and 16.68 percent over the past 90 days as of September 5, 2026, delivering a one-year total shareholder return of 48.55 percent, which reflects how recent clinical data, guidance updates and pipeline headlines have been progressively priced in. The same Simply Wall St analysis cites a frequently referenced fair-value estimate of 66.21 dollars per share, only slightly below a recent closing price of 66.82 dollars, while an alternative discounted cash flow approach yields a higher fair-value indication of 118.83 dollars, highlighting that valuation opinions currently diverge depending on assumptions about the long-term pipeline.

MarketBeat’s latest data on analyst sentiment indicates that Bristol-Myers Squibb currently carries a consensus rating of Moderate Buy with an average price target of 66.06 dollars, broadly in line with the recent trading band and suggesting that, on average, covering analysts see the shares as fairly valued to modestly undervalued at current levels. The same MarketBeat alert notes that institutional investors such as the Saudi Central Bank have recently adjusted their positions, which many retail investors regard as a signal that professional money continues to engage with the stock.

Product focus: Camzyos in hypertrophic cardiomyopathy

A recent Simply Wall St article points out that Bristol-Myers Squibb is in focus following fresh five-year data on Camzyos in obstructive hypertrophic cardiomyopathy, alongside a voluntary enrollment pause in zola-cel autoimmune trials, illustrating both the potential and the risk embedded in the company’s pipeline. The pipeline-focused discussion underscores that longer-term clinical data on cardiovascular drugs such as Camzyos can meaningfully reinforce the case for sustained Growth Portfolio expansion, especially as legacy products face competitive pressure.

Stock performance and trading context

As of the last trading day referenced in MarketBeat’s latest alerts, shares of Bristol-Myers Squibb opened at 66.85 dollars on the New York Stock Exchange on September 4, 2026, a level that places the stock close to the 66.82 dollar price cited in the Simply Wall St valuation piece and near the consensus price target of 66.06 dollars. The MarketBeat trading snapshot therefore shows that the market price currently sits within a narrow band around prevailing analyst expectations, even after the strong one-year total shareholder return documented by Simply Wall St.